X0306 4 2018-09-18 0 0000891293 CTI BIOPHARMA CORP ctic 0001276750 KIRSKE DAVID 3101 WESTERN AVE., SUITE 800 SEATTLE WA 98121 0 1 0 0 EVP, Chief Financial Officer Non-Qualified Stock Option (right to buy) 1.88 2018-09-18 4 A 0 125000 0 A 2028-09-18 Common Stock 125000 125000 D The stock options will fully vest upon the Compensation Committee's certification of the European Medicines Agency approval of the Marketing Authorization Application for Pacritinib, assuming that such approval occurs no later than September 30, 2019. David H. Kirske 2018-09-20